Summary
Pfizer Inc. reported its financial results for the quarter and six months ended June 30, 2013. The company experienced a notable decrease in revenues, primarily attributed to the loss of exclusivity for key products like Lipitor in various markets, leading to increased generic competition. Despite the revenue decline, Pfizer managed to significantly boost its net income, largely driven by a substantial gain from the disposal of its Animal Health business (Zoetis) and a substantial patent litigation settlement income. The company's strategic divestitures, including Zoetis and the Nutrition business, are reshaping its portfolio, with a focus on streamlining operations and a commitment to future innovation. Operationally, Pfizer saw its income from continuing operations increase due to favorable legal settlements and cost-reduction initiatives, though these were partially offset by ongoing business challenges like loss of exclusivity and market competition. The company continued its share repurchase program, demonstrating a commitment to returning capital to shareholders, while also managing its debt effectively. Investors should note the significant impact of one-time events on the reported net income, while the core operational performance reflects the ongoing challenges and strategic adjustments within the pharmaceutical industry.
Financial Highlights
53 data points| Revenue | $12.97B |
| Cost of Revenue | $2.24B |
| Gross Profit | $10.73B |
| SG&A Expenses | $3.59B |
| Operating Income | $6.17B |
| Interest Expense | $356.00M |
| Net Income | $14.10B |
| EPS (Basic) | $2.00 |
| EPS (Diluted) | $1.98 |
| Shares Outstanding (Basic) | 7.04B |
| Shares Outstanding (Diluted) | 7.12B |
Key Highlights
- 1Total revenues for the quarter and six months ended June 30, 2013, decreased by 7% and 9% respectively, compared to the prior year periods, largely due to product losses of exclusivity, including Lipitor.
- 2Net income attributable to Pfizer Inc. saw a substantial increase, reaching $14.1 billion for the quarter and $16.8 billion for the six months, significantly boosted by a $10.4 billion gain on the disposal of the Zoetis animal health business and a $1.4 billion patent litigation settlement income.
- 3Income from continuing operations before taxes increased by 28% for the quarter and 43% for the six months, driven by favorable legal settlements and cost management, despite lower revenues.
- 4The company repurchased approximately $7.9 billion of its common stock in the first six months of 2013 as part of its share repurchase program.
- 5Pfizer's cash and cash equivalents decreased significantly to $2.4 billion at June 30, 2013, from $10.1 billion at December 31, 2012, primarily due to cash used in investing and financing activities, including share repurchases and investment purchases.
- 6Research and development expenses decreased by 4% for the quarter and 9% for the six months, reflecting ongoing cost-reduction initiatives.
- 7The company reaffirmed its full-year 2013 financial guidance, projecting reported diluted EPS between $3.07 to $3.22.